{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01648751",
            "orgStudyIdInfo": {
                "id": "PRO09090064"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01HD061811",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01HD061811"
                }
            ],
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse",
            "officialTitle": "Impact of Vaginal Estrogen in the Treatment of Symptomatic Mild Pelvic Organ Prolapse With Pelvic Floor Physical Therapy",
            "therapeuticArea": [
                "Other"
            ],
            "study": "vaginal-estrogen-and-pelvic-floor-physical-therapy-in-women-with-symptomatic-mild-prolapse"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2012-05"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2012-07-19",
            "studyFirstSubmitQcDate": "2012-07-23",
            "studyFirstPostDateStruct": {
                "date": "2012-07-24",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-02-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Pamela Moalli",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "Pamela Moalli",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "American Urogynecologic Society",
                    "class": "OTHER"
                },
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                },
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                },
                {
                    "name": "Pfizer",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized controlled trial in which women with symptomatic mild pelvic organ prolapse undergoing Pelvic Floor Physical Therapy (PFPT) receive vaginal estrogen versus placebo to see if a combined approach to treatment leads to improvement in clinical outcomes. The investigators predict that PFPT in combination with vaginal estrogen will lead to decreased pelvic floor symptoms and improved anatomical support corroborated by biomarker data.",
            "detailedDescription": "The pathogenesis of pelvic organ prolapse (POP) is unknown. Few studies have correlated patient symptoms and amount of prolapse with biomarkers. POP has traditionally been managed with a pessary or surgery. Recent studies suggest a reduction in POP symptoms following Pelvic Floor Physical Therapy (PFPT). Vaginally delivered hormones are also commonly used to treat prolapse symptoms, with little evidence supporting a clinical benefit. The investigators hypothesize that the optimal approach to improving prolapse symptoms in the patient with mild prolapse requires re-alignment and strengthening of levator muscles via PFPT, and optimization of tissue integrity via local estrogen therapy. The investigators propose to test this hypothesis in a randomized controlled trial in which women with symptomatic mild prolapse opting for PFPT, receive treatment with PFPT in combination with vaginal estrogen versus placebo. The investigators predict that the combined approach will lead to decreased symptoms and improved anatomical support corroborated by biomarker data."
        },
        "conditionsModule": {
            "conditions": [
                "Pelvic Organ Prolapse"
            ],
            "keywords": [
                "Pelvic organ prolapse",
                "Pelvic floor physical therapy",
                "Vaginal estrogen",
                "Placebo"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 53,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Vaginal estrogen",
                    "type": "EXPERIMENTAL",
                    "description": "Patients in the experimental group will receive vaginal estrogen cream",
                    "interventionNames": [
                        "Drug: Vaginal estrogen"
                    ]
                },
                {
                    "label": "Placebo cream",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Patients in the comparison group will receive placebo vaginal cream",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Vaginal estrogen",
                    "description": "1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter",
                    "armGroupLabels": [
                        "Vaginal estrogen"
                    ],
                    "otherNames": [
                        "Premarin vaginal cream"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter",
                    "armGroupLabels": [
                        "Placebo cream"
                    ],
                    "otherNames": [
                        "Placebo cream"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Global impression of improvement in prolapse symptoms, using the PGI-I",
                    "description": "To determine the impact of vaginally delivered estrogen on global impression of improvement in women with symptomatic mild pelvic organ prolapse who are undergoing pelvic floor physical therapy",
                    "timeFrame": "6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pelvic floor symptoms, using the PFDI-20",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Quality of life, using the PFIQ-7",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Sexual function, using the PISQ-12",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Pelvic organ prolapse stage, using the POP-Q exam",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Collagenase activity",
                    "description": "Vaginal swabs collected from the posterior fornix will be used for biochemical analysis",
                    "timeFrame": "6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Women in good health aged 40-80\n* Has symptoms of pelvic organ prolapse; answers yes to at least 1 of the following questions:\n\nDo you feel or see a vaginal bulge? Do you feel pressure in the vagina?\n\n* Meets POP-Q criteria on exam for stage I, II, or III prolapse\n* Interested in PFPT for management of POP\n* Normal mammogram within 1 year of enrollment\n\nExclusion Criteria:\n\n* Prior surgery for prolapse or incontinence\n* Other prior interventions for prolapse (e.g. pessary, PFPT)\n* Previous bilateral salpingo-oophorectomy (women with 1 ovary will be eligible)\n* Known liver dysfunction\n* Connective tissue diseases known to affect collagen or elastin remodeling (including: Lupus, Rheumatoid Arthritis, Scleroderma, Sjogrens syndrome, Marfan syndrome, and Ehlers-Danlos syndrome)\n* Unevaluated abnormal vaginal bleeding or abnormal pap smear in the previous year\n* BMI \\> 35 kg/m2\n* Estrogen therapy (including birth control) in the previous year\n* Current or prior breast or pelvic malignancy (ovarian, tubal, uterine, cervical or vaginal)\n* Contraindication to hormone use (i.e. thromboembolic disorder, use of anti-coagulants, coronary artery disease, history of stroke)",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "40 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Laura C Skoczylas, MD, MS",
                    "role": "CONTACT",
                    "phone": "323-857-2238",
                    "email": "lauraskoczylas@gmail.com"
                },
                {
                    "name": "Pamela Moalli, MD, PhD",
                    "role": "CONTACT",
                    "email": "moalpa@mail.magee.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Laura C Skoczylas, MD, MS",
                    "affiliation": "University of Pittsburgh",
                    "role": "STUDY_DIRECTOR"
                },
                {
                    "name": "Pamela Moalli, MD, PhD",
                    "affiliation": "University of Pittsburgh",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Magee-Womens Hospital, University of Pittsburgh",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lori Geraci, BS",
                            "role": "CONTACT",
                            "phone": "412-641-2634"
                        },
                        {
                            "name": "Laura C Skoczylas, MD, MS",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Pamela Moalli, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011391",
                    "term": "Prolapse"
                },
                {
                    "id": "D000056887",
                    "term": "Pelvic Organ Prolapse"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020763",
                    "term": "Pathological Conditions, Anatomical"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14261",
                    "name": "Prolapse",
                    "asFound": "Prolapse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28618",
                    "name": "Pelvic Organ Prolapse",
                    "asFound": "Pelvic Organ Prolapse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22519",
                    "name": "Pathological Conditions, Anatomical",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004967",
                    "term": "Estrogens"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "asFound": "USA",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8115",
                    "name": "Estrogens, Conjugated (USP)",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}